* Ranibizumab injection (Lucentis) is the first drug approved for the treatment of diabetic macular edema. It reduces endothelial cell proliferation, vascular leakage, and new blood vessel formation. Clinical trials found that the drug, which is administered monthly in an intravitreal injection, improved vision.
* Common adverse effects include bleeding into the conjunctiva, eye pain, eye floaters, and increased intraocular pressure.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: email@example.com.